Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 5;21(1):164.
doi: 10.1186/s13075-019-1937-4.

The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis

Yoshiya Tanaka  1 , Josef S Smolen  2 , Heather Jones  3 , Annette Szumski  4 , Lisa Marshall  3 , Paul Emery  5
Affiliations

The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis

Yoshiya Tanaka et al. Arthritis Res Ther. .

Abstract

Background: Biologic disease-modifying antirheumatic drugs (bDMARDs) are important options for managing rheumatoid arthritis (RA). Once patients achieve disease control, clinicians may consider dose reduction or withdrawal of the bDMARD. Results from published studies indicate that some patients will maintain remission; however, others will flare. We analyzed data from three etanercept down-titration studies in patients with RA to determine what extent of remission provides the greatest predictability of maintaining remission following dose reduction or discontinuation.

Methods: Patients with moderate to severe RA from the PRESERVE, PRIZE, and Treat-to-Target (T2T) randomized controlled trials were included. We determined the proportion of patients achieving remission with etanercept at the last time point in the induction period, and sustained remission (last two time points), according to the Disease Activity Score 28-joints (DAS28), the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Boolean criteria, and the clinical disease activity index (CDAI). We also calculated the proportion achieving DAS28 deep remission (DAS28 ≤ 1.98), sustained deep remission (last two time points), and low disease activity (LDA), and LDA according to the CDAI. Then, we evaluated whether they maintained remission or LDA following etanercept dose reduction or withdrawal.

Results: Patients achieving sustained and/or deep remission were more likely than patients achieving remission or LDA to maintain remission/LDA after etanercept dose reduction or withdrawal. In PRESERVE, the proportions of patients with DAS28 sustained deep remission, deep remission, sustained remission, remission, and LDA who maintained remission following etanercept dose reduction were 81%, 67%, 58%, 56%, and 36%, respectively, P < 0.001 for trend. In PRESERVE, this trend was significant when etanercept was discontinued and when ACR/EULAR Boolean and CDAI remission criteria were used. Although some sample sizes were small, the PRIZE and T2T studies also demonstrated response trends according to ACR/EULAR Boolean and CDAI remission criteria, and T2T demonstrated response trends according to DAS28.

Conclusions: These results suggest that patients achieving disease control according to a stringent definition, such as sustained ACR/EULAR Boolean or CDAI remission, or a new definition of sustained deep remission by DAS28, have a higher probability of remaining in remission or LDA following etanercept dose reduction or withdrawal.

Trial registration: PRESERVE: ClinicalTrials.gov identifier: NCT00565409 , registered 30 November 2007; PRIZE: ClinicalTrials.gov identifier: NCT00913458 , registered 4 June 2009; T2T: ClinicalTrials.gov identifier: NCT01578850 , registered 17 April 2012.

Keywords: ACR/EULAR Boolean; Anti-TNF; CDAI; DAS28; Dose reduction; Etanercept; Remission; Rheumatoid arthritis; Withdrawal.

PubMed Disclaimer

Conflict of interest statement

YT has received speaking fees and/or honoraria from Daiichi-Sankyo, Astellas, Eli Lilly, Chugai, Sanofi, AbbVie, Pfizer, YL Biologics, Bristol-Myers, GlaxoSmithKline, UCB, Mitsubishi-Tanabe, Novartis, Eisai, Takeda, Janssen, and Asahi-kasei and has received research grants from Mitsubishi-Tanabe, Bristol-Myers, Eisai, Chugai, Takeda, AbbVie, Astellas, Daiichi-Sankyo, Ono, MSD, and Taisho-Toyama. JSS has received research grant support from Abbott, BMS, MSD, Pfizer, Roche, and UCB and consultation and/or speaking honoraria from Abbott, Astra-Zeneca, BMS, Celgene, Celltrion, Glaxo, Janssen, MSD, Pfizer, Roche, Samsung, Sanofi-Aventis, and UCB. HJ and LM were employees of Pfizer at the time the manuscript was written. AS is an employee of Syneos Health and was contracted by Pfizer to provide statistical support for the development of this paper. PE has received grant/research support and consultancy fees from AbbVie, BMS, Lilly, MSD, Novartis, Pfizer, Roche, Samsung, Sandoz, and UCB.

No nonfinancial competing interest exists for any author.

Figures

Fig. 1
Fig. 1
Proportion of patients in the PRESERVE study maintaining remission or LDA in period 2, according to response category in period 1 for the remission criteria of DAS28 (a), ACR/EULAR Boolean (b), and CDAI (c). ACR American College of Rheumatology, CDAI Clinical Disease Activity Index, DAS28 Disease Activity Score in 28 joints, ETN50 etanercept 50 mg, EULAR European League Against Rheumatism, LDA low disease activity, MTX methotrexate, PBO placebo
Fig. 2
Fig. 2
Proportion of patients in the PRIZE study maintaining remission or LDA in period 2, according to response category in period 1 for the remission criteria of DAS28 (a), ACR/EULAR Boolean (b), and CDAI (c). ACR American College of Rheumatology, CDAI Clinical Disease Activity Index, DAS28 Disease Activity Score in 28 joints, ETN50 etanercept 50 mg, EULAR European League Against Rheumatism, LDA low disease activity, MTX methotrexate, PBO placebo
Fig. 3
Fig. 3
Proportion of patients in the T2T study maintaining remission or LDA in period 2, according to response category in period 1 for the remission criteria of DAS28 (a), ACR/EULAR Boolean (b), and CDAI (c). ACR American College of Rheumatology, CDAI Clinical Disease Activity Index, csDMARDs conventional synthetic disease-modifying antirheumatic drugs, DAS28 Disease Activity Score in 28 joints, ETN50 etanercept 50 mg, EULAR European League Against Rheumatism, LDA low disease activity, MTX methotrexate, PBO placebo
See this image and copyright information in PMC

References

    1. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–977. doi: 10.1136/annrheumdis-2016-210715. - DOI - PubMed
    1. Lau CS, Chia F, Harrison A, Hsieh T-Y, Jain R, Jung SM, et al. APLAR rheumatoid arthritis treatment recommendations. Int J Rheum Dis. 2015;18(7):685–713. doi: 10.1111/1756-185X.12754. - DOI - PubMed
    1. Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1–26. doi: 10.1002/art.39480. - DOI - PubMed
    1. Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75:3–15. doi: 10.1136/annrheumdis-2015-207524. - DOI - PMC - PubMed
    1. van Nies JAB, Tsonaka R, Gaujoux-Viala C, Fautrel B, van der Helm-van Mil AHM. Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts. Ann Rheum Dis. 2015;74:806–812. doi: 10.1136/annrheumdis-2014-206047. - DOI - PubMed

Publication types

Associated data

Grants and funding